Research menu
Jump to menu

Publications:  Dr Peter Szlosarek

Fennell DA, Kirkpatrick E, Cozens K et al.(2018). CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials vol. 19, (1)
Khadeir R, Szyszko T, Szlosarek PW(2017). Optimizing arginine deprivation for hard-to-treat cancers. Oncotarget vol. 8, (57) 96468-96469.
Beddowes E, Spicer J, Chan PY et al.(2017). Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. J Clin Oncol vol. 35, (16) 1778-1785.
Chan PY, Hall P, Hay G et al.(2017). A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell Melanoma Res vol. 30, (6) 558-562.
Szlosarek PW, Steele JP, Nolan L et al.(2017). Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA Oncol vol. 3, (1) 58-66.
Szlosarek PW, Steele JP, Nolan L et al.(2017). Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial. JAMA Oncology vol. 3, (1) E1-E9.
Szyszko TA, Bomalaski JS, Goh V et al. (2016). TRAP substudy: assessment of 18-FLT PET/CT to examine tumour proliferation in patients with ASS1-deficient thoracic cancers treated with arginine deiminase (ADI)-PEG20, pemetrexed and cisplatin. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. vol. 43, S354-S354.
Locke M, Ghazaly E, Freitas MO et al.(2016). Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. Cell Reports vol. 16, (6) 1604-1613.
Szlosarek PW, Locke M, Ghazaly E et al. (2016). Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1 in cancer. vol. 76,
Szlosarek PW, Szyszko T, Pacey S et al. (2016). 18-FLT-PET/CT as an imaging biomarker in patients with ASS1-deficient thoracic cancers treated with ADI-PEG20, pemetrexed and cisplatin. JOURNAL OF CLINICAL ONCOLOGY. vol. 34,
Karydis I, Chan PY, Wheater M et al.(2016). Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology vol. 5, (5)
Szyszko TA, Yip C, Szlosarek P et al.(2016). The role of new PET tracers for lung cancer. Lung cancer (Amsterdam, Netherlands) vol. 94, 7-14.
Burrows N, Cane G, Robson M et al.(2016). Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20). Sci Rep vol. 6,
Klionsky DJ, Abdelmohsen K, Abe A et al.(2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy vol. 12, (1) 1-222.
Nathan P, Cohen V, Coupland S et al.(2015). Uveal Melanoma UK National Guidelines. Eur J Cancer vol. 51, (16) 2404-2412.
Phillips MM, Khadeir R, Tookman L et al. (2015). Macrophages promote resistance to pegylated arginine deiminase in malignant pleural mesothelioma. CANCER RESEARCH. vol. 75,
Pazmandi J, O'Neill KS, Scheck AC et al. (2015). The ketogenic diet alters the expression of microRNAs that play key roles in tumor development. CANCER RESEARCH. vol. 75,
Khadeir RS, Phillips MM, Sgoo MS et al. (2015). Widespread deficiency of ASS1 in uveal melanoma and sensitivity to pegylated arginine deiminase. CANCER RESEARCH. vol. 75,
Miraki-Moud F, Ghazaly E, Ariza-McNaughton L et al.(2015). Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood vol. 125, (26) 4060-4068.
Szlosarek PW, Spicer JF, Szyszko T et al. (2015). Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
Szlosarek PW, Lee S, Pollard PJ(2014). Rewiring mitochondrial pyruvate metabolism: switching off the light in cancer cells?. Mol Cell vol. 56, (3) 343-344.
Cutts R, Jithesh PV, Delage B et al. (2014). Gene expression analysis of argininosuccinate synthetase loss and the effects of pegylated arginine deiminase in malignant pleural mesothelioma. CANCER RESEARCH. vol. 74,
Szlosarek PW(2014). Arginine deprivation and autophagic cell death in cancer. Proc Natl Acad Sci U S A vol. 111, (39) 14015-14016.
Ghazaly EA, Luong P, Chmielewska-Kassassir M et al. (2014). Metabolomic analysis of pegylated arginine deiminase treatment in patients with malignant pleural mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
Szlosarek PW, Steele JP, Nolan L et al. (2014). Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
Allen MD, Luong P, Hudson C et al.(2014). Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res vol. 74, (3) 896-907.
Rintoul RC, Rassl DM, Maskell N et al.(2014). MesobanK - a UK based bioresource for malignant mesothelioma. LUNG CANCER vol. 83, S82-S82.
Phillips MM, Sheaff MT, Szlosarek PW(2013). Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat vol. 45, (4) 251-262.
Miraki-Moud F, Ariza-McNaughton L, Ghazaly EA et al. (2013). Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo. BLOOD. vol. 122,
Sommerlad M, Purdie K, Rizvi H et al. (2013). Vemurafenib, photosensitivity and human papillomavirus infection: an emerging story. BRITISH JOURNAL OF DERMATOLOGY. vol. 169, 9-9.
Zheng L, MacKenzie ED, Karim SA et al.(2013). Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab vol. 1, (1)
Szlosarek PW, Luong P, Phillips MM et al.(2013). Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol vol. 31, (7) e111-e113.
Syed N, Langer J, Janczar K et al.(2013). Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis vol. 4,
Matin RN, Szlosarek P, McGregor JM et al.(2013). Synchronous melanoma and renal carcinoma: a clinicopathological study of five cases. Clin Exp Dermatol vol. 38, (1) 47-49.
Lewis A, Hough N, Woolf DK et al.(2013). Systemic therapy in the management of non small cell lung cancer (NSCLC): The real world experience. LUNG CANCER vol. 79, S17-S17.
Hough N, Lewis A, Woolf DK et al.(2013). Three years experience of chemotherapy for small cell lung cancer at a tertiary referral centre. LUNG CANCER vol. 79, S65-S65.
Coward JIG, Ding N-L, Feakins R et al.(2012). Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report. Med Oncol vol. 29, (4) 2623-2625.
Delage B, Luong P, Maharaj L et al.(2012). Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis vol. 3,
Hatzimichael E, Dasoula A, Syed N et al. (2012). Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. vol. 30,
Wang H, Lee S, Nigro CL et al.(2012). NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer vol. 106, (8) 1446-1452.
Matin RN, Gonzalez D, Thompson L et al.(2012). KIT and BRAF mutational status in a patient with a synchronous lentigo maligna melanoma and a gastrointestinal stromal tumor. Am J Clin Dermatol vol. 13, (1) 64-65.
Syed N, Coley HM, Sehouli J et al.(2011). Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res vol. 71, (9) 3317-3327.
Allen M, Syed N, Luong F et al.(2011). Epigenetic silencing of argininosuccinate synthetase renders human bladder cancer cells sensitive to pegylated arginine deiminase. CANCER RESEARCH vol. 71,
Szlosarek PW, Luong F, Clear A et al.(2011). Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia. CANCER RESEARCH vol. 71,
Syed N, O'Neilli K, Hughes M et al.(2011). Transcriptional silencing disrupts two levels of arginine biosynthesis in glioblastoma multiforme: a novel, targeted therapeutic strategy for high grade gliomas. CANCER RESEARCH vol. 71,
Delage B, Fennell DA, Nicholson L et al.(2010). Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer vol. 126, (12) 2762-2772.
Nicholson LJ, Smith PR, Hiller L et al.(2009). Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer vol. 125, (6) 1454-1463.
Matin RN, Harwood CA, McAndrew L et al. (2009). A clinicopathological study of cases of synchronous melanoma and renal carcinoma. BRITISH JOURNAL OF DERMATOLOGY. vol. 161, 19-19.
Lim SL, Smith P, Syed N et al.(2008). Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. BRIT J CANCER vol. 98, (8) 1452-1456.
Szlosarek PW, Grimshaw MJ, Wilbanks GD et al.(2007). Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer vol. 121, (1) 6-11.
Szlosarek PW, Klabatsa A, Pallaska A et al.(2006). In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res vol. 12, (23) 7126-7131.
Szlosarek PW, Fennell DA, Rudd RM et al.(2006). A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma. LUNG CANCER vol. 54, S54-S54.
Szlosarek P, Charles KA, Balkwill FR(2006). Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer vol. 42, (6) 745-750.
Szlosarek PW, Grimshaw MJ, Kulbe H et al.(2006). Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther vol. 5, (2) 382-390.
Kulbe H, Hagemann T, Szlosarek PW et al.(2005). The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res vol. 65, (22) 10355-10362.
Szlosarek PW, Grimshaw MJ, Wilbanks GD et al. (2004). Regulation and expression of argininosuccinate synthetase in human ovarian cancer. BRITISH JOURNAL OF CANCER. vol. 91, S57-S57.
Szlosarek P, Balkwill F(2004). The inflammatory cytokine network of epithelial cancer: therapeutic implications. Novartis Found Symp vol. 256, 227-237.
Szlosarek PW, Balkwill FR(2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol vol. 4, (9) 565-573.
Nicholson S, Guile K, John J et al.(2003). A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. MELANOMA RES vol. 13, (4) 389-393.
Szlosarek PW(2001). Recent advances in palliative care - United Kingdom continues to lead in palliative care. BRIT MED J vol. 322, (7280) 234-234.
Return to top